Gilbert W Gleim

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
  2. ncbi The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy
    Jonathan C Fox
    Merck Research Laboratories, BLX-21, P.O. Box 4, West Point, PA 19486, USA
    J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004
  3. ncbi Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
  4. ncbi Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiovasc Drugs 5:17-22. 2005
  5. ncbi Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
  6. ncbi Effects of losartan on diabetic maculopathy in type 2 diabetic patients
    Gilbert W Gleim
    J Intern Med 255:304-5; author reply 306-7. 2004
  7. ncbi The impact of morbid events on survival following hospitalization for complicated myocardial infarction
    Kenneth Dickstein
    University of Bergen, Cardiology Division, Stavanger University Hospital, 4011, Stavanger, Norway
    Eur J Heart Fail 8:74-80. 2006

Detail Information

Publications7

  1. ncbi A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
    ..Because patients with hypertension may require >1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications...
  2. ncbi The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy
    Jonathan C Fox
    Merck Research Laboratories, BLX-21, P.O. Box 4, West Point, PA 19486, USA
    J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004
    ..The use of two medications will achieve goal BP in more patients than monotherapy. This observation is important in treatment of high-risk patients with diabetes...
  3. ncbi Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
    ....
  4. ncbi Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiovasc Drugs 5:17-22. 2005
    ..Fixed combination ARB/hydrochlorothiazide agents make sense as initial therapy for patients in whom BP is >20/10 mm Hg above goal...
  5. ncbi Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
    ..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
  6. ncbi Effects of losartan on diabetic maculopathy in type 2 diabetic patients
    Gilbert W Gleim
    J Intern Med 255:304-5; author reply 306-7. 2004
  7. ncbi The impact of morbid events on survival following hospitalization for complicated myocardial infarction
    Kenneth Dickstein
    University of Bergen, Cardiology Division, Stavanger University Hospital, 4011, Stavanger, Norway
    Eur J Heart Fail 8:74-80. 2006
    ..Little is known about the importance of morbid events with respect to longer term survival following MI hospital discharge...